Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Nontransfusion-dependent thalassemia (NTDT) patients may develop iron overload and its associated complications despite receiving only occasional or no transfusions. The present 1-year, randomized, double-blind, placebo-controlled THALASSA (Assessment of Exjade in Nontransfusion-Dependent Thalassemia) trial assessed the efficacy and safety of deferasirox in iron-overloaded NTDT patients. A total of 166 patients were randomized in a 2:1:2:1 ratio to starting doses of 5 or 10 mg/kg/d of deferasirox or placebo. The means ± SD of the actual deferasirox doses received over the duration of the study in the 5 and 10 mg/kg/d starting dose cohorts were 5.7 ± 1.4 and 11.5 ± 2.9 mg/kg/d, respectively. At 1 year, the liver iron concentration (LIC) decreased significantly compared with placebo (least-squares mean [LSM] ± SEM, −2.33 ± 0.7 mg Fe/g dry weight [dw], P = .001, and −4.18 ± 0.69 mg Fe/g dw, P < .001) for the 5 and 10 mg/kg/d deferasirox groups, respectively (baseline values [means ± SD], 13.11 ± 7.29 and 14.56 ± 7.92 mg Fe/g dw, respectively). Similarly, serum ferritin decreased significantly compared with placebo by LSM −235 and −337 ng/mL for the deferasirox 5 and 10 mg/kg/d groups, respectively (P < .001). In the placebo patients, LIC and serum ferritin increased from baseline by 0.38 mg Fe/g dw and 115 ng/mL (LSM), respectively. The most common drug-related adverse events were nausea (n = 11; 6.6%), rash (n = 8; 4.8%), and diarrhea (n = 6; 3.6%). This is the first randomized study showing that iron chelation with deferasirox significantly reduces iron overload in NTDT patients with a frequency of overall adverse events similar to placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IRON ABSORPTION AND LOADING IN β-THALASSÆMIA INTERMEDIA
Pippard, M. J., Warner, G. T., Callender, S. T., & Weatherall, D. J. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92175-5 · Cited by 419
Liver iron concentrations and urinary hepcidin in -thalassemia
Origa, R., Galanello, R., Ganz, T., Giagu, N., Maccioni, L., Faa, G., & Nemeth, E. (2007) · Haematologica · doi:10.3324/haematol.10842 · Cited by 365
Self-citation
Cited by
Angelucci, E., Matthes-Martin, S., Baronciani, D., Bernaudin, F., Bonanomi, S., Cappellini, M. D., Dalle, J.-H., Di Bartolomeo, P., de Heredia, C. D., Dickerhoff, R., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.099747 · Cited by 399
Self-citationIron overload in thalassemia: different organs at different rates
Taher, A. T., & Saliba, A. N. (2017) · Hematology · doi:10.1182/asheducation-2017.1.265 · Cited by 355
Self-citationNon-transfusion-dependent thalassemias
Musallam, K. M., Rivella, S., Vichinsky, E., & Rachmilewitz, E. A. (2013) · Haematologica · doi:10.3324/haematol.2012.066845 · Cited by 326
Angelucci, E., Li, J., Greenberg, P., Wu, D., Hou, M., Montaňo Figueroa, E. H., Rodriguez, M. G., Dong, X., Ghosh, J., Izquierdo, M., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-0916 · Cited by 120
Iron overload in β-thalassemia intermedia: an emerging concern
Musallam, K. M., Cappellini, M. D., & Taher, A. T. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32835f5a5c · Cited by 50
Self-citation
Metadata
- Authors
- Taher, A. T., Porter, J., Viprakasit, V., Kattamis, A., Chuncharunee, S., Sutcharitchan, P., Siritanaratkul, N., Galanello, R., Karakas, Z., Lawniczek, T., Ros, J., Zhang, Y., Habr, D., & Cappellini, M. D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-08-02
- Volume
- 120
- Issue
- 5
- Pages
- 970-977
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1992773264
- Cited by
- 147
- References
- 2
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1182/blood-2012-02-412692
- The paper
- Taher, A. T., Porter, J., Viprakasit, V., Kattamis, A., Chuncharunee, S., Sutcharitchan, P., Siritanaratkul, N., Galanello, R., Karakas, Z., Lawniczek, T., Ros, J., Zhang, Y., Habr, D., & Cappellini, M. D. (2012). Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. https://doi.org/10.1182/blood-2012-02-412692
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.